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Abstract
Chronic venous disease (CVD) is defined as any morphological and functional abnormalities of long duration 
manifested either by symptoms and/or signs indicating the need for investigation and/or care. The pathophysi-
ological mechanism of CVD can be characterized by reflux, obstruction, or a combination of both, which leads 
to increased venous pressure. 
Compression therapy remains the gold standard of the conservative treatment of CVD in all stages. The possible 
forms of compression therapy are elastic stocking, non-elastic and elastic bandages, and intermittent pneumatic 
compression. Compression bandages have been proven to improve the healing of venous ulcers, in comparison 
with standard care without compression therapy.
In the last years, inflammation has been shown to play an important role in the pathophysiology of CVD. The 
influence of the altered shear stress on the endothelial cells (EC) causes EC to release inflammatory molecules, 
chemokines, vasoactive agents, express selectins, and prothrombotic precursors such as ICAM-1, MCP-1, MIP 1b, 
VCAM, L-selectin, E-selectin, IL-1b, IL-4, IL-6, IL-8, IL-12p40, IL-13, G-CSF, GM-CSF, IFN-g, TNF-a, and 
MIP-1a.
Several studies have been performed to investigate the influence of compression therapy on the level of various 
inflammatory biomarkers in patients with CVD. In these studies level of the most inflammatory molecules, such 
as IL-1b, IL-6, IL-8, IL-12p40, G-CSF, GM-CSF, IFN-g, TNF-a, VEGF, MMP 3, 8, 9 and TIMP-1 decreased 
after the therapy.
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Introduction
Chronic venous disease (CVD) is defined as any 
morphological and functional abnormalities of long 
duration manifested either by symptoms and/or signs 
indicating the need for investigation and/or care [1]. The 
prevalence of CVD has been previously investigated in 
many epidemiological studies that have been carried all 
around the world. The reported incidence of CVD rang-
es between 20% and 60%, depending on the region 
where the research was conducted, different criteria for 
patient selection, disease definition, different imaging 
techniques used, and exposure to risk factors [2]. The 
reported prevalence of CVD was higher in the western 
populations of developed regions that are exposed to 
various risk factors such as sedentary lifestyle, low fiber 
diet, or constipation [3]. More advanced stages of CVD 
(C3–C6 in the CEAP classification) affect about 5% 
of the population, and the end stages (C5–C6) of the 
CVD – about 1–2% [4]. The presence of CVD may 
be associated with lower quality of life — almost 30% 
of patients present with symptoms of depression [5]. 
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Pathophysiology of CVD
The pathophysiological mechanism of CVD can be 
characterized by reflux, obstruction, or a combination 
of both. Both lead to increased ambulatory venous 
pressure. Other factors may be e.g. failure of the calf 
and foot muscle pomp (in neuromuscular problems) [5]. 
The most frequent cause of venous hypertension is 
valvular incompetence (70–80% of cases), while 
isolated outflow obstruction is found in ca. 2 %. Val-
vular incompetence may be secondary to deep vein 
thrombosis in 18–25%, or due to congenital anomaly 
in 1–3% [6] 
The role of inflammation in a CVD
In the last years, inflammation has been shown to play 
an important role in the pathophysiology of CVD [7]. 
Venous hypertension in the lower limbs leads to a vi-
cious circle of vascular and inflammatory phenomena 
that increases hypertension even more. High venous 
pressure in the lower extremities leads to leukocyte 
accumulation due to leukocyte adhesion to the en-
dothelium and migration through the endothelium 
of small vessels [8]. It also results in a reduction of 
shear stress (SS) ― the main regulator of endothelial 
activation state that promotes pathological changes of 
venous valves and vein wall [9]. Low SS leads to local 
inflammation, through the activation of endothelial cells 
(ECs) and leukocytes, that release vasoactive agents, 
express selectins, inflammatory molecules, chemok-
ines, and prothrombotic precursors, and through the 
infiltration of inflammatory cells into venous walls and 
leaflets [10, 11]. Changes in EC signaling result in in-
creased production of inflammatory biomarkers, e.g. 
chemokines, cytokines, growth factors, proteases, and 
others, that cause worsening of the inflammatory pro-
cess [12]. Many studies report an increased expression 
of inflammatory markers in vitro, in pre-clinical studies, 
and in patients with CVD, which confirms the role of 
inflammation in CVD [13].
Compression therapy — a gold standard 
in a treatment of CVD
Compression therapy remains the gold standard of 
the conservative treatment of CVD in all stages, because 
of its non-invasive nature, ease of use, and efficacy of 
reducing venous hypertension which is a main patho-
physiological mechanism of CVD. The possible forms 
of compression therapy are elastic stocking, non-elas-
tic and elastic bandages, and intermittent pneumatic 
compression [5]. 
In the last decades, elastic stockings have been the 
cornerstone of conservative treatment of C0–C4 CVD. 
Despite their popularity, evidence of the efficacy for 
this type of compression remains unclear and is based 
on the lack of randomized controlled trials for both 
primary and post-thrombotic CVD [14, 15]. However, 
there is some evidence, based on non-RCTs and clinical 
experience supporting their use to improve patients’ 
symptoms [15] and quality of life [16]. 
Compression bandages have been proven to im-
prove the healing of venous ulcers, in comparison with 
standard care without compression therapy [17]. Types 
of bandages include traditional systems with elastic 
components and non-elastic compression systems [18]. 
High compression systems with a sustained compres-
sion of at least 40 mm Hg with a four-layer bandage 
have been shown to be more effective than the lower 
grades of compression [19]. Compression bandages are 
recommended as the initial treatment in patients with 
venous leg ulcers [5].
Inflammatory biomarkers  
in patients with CVD
In the last years, many studies confirmed an in-
creased level of proinflammatory molecules in patients 
with CVD. The influence of the altered shear stress on 
the endothelial cells (EC) causes EC to release inflamma-
tory molecules, chemokines, vasoactive agents, express 
selectins, and prothrombotic precursors [20]. ICAM-1 
is a molecule responsible for the detection of changes 
in mechanical stress forces and SS, promoting leuko-
cyte recruitment, adhesion, and transmigration [21]. 
Overexpression of ICAM-1 in EC has been shown in 
several studies [22, 23]. MCP-1, macrophage inflam-
matory protein 1b, vascular cell adhesion molecule 
(VCAM), as well as L-selectin, E-selectin, and ICAM-1 
enhance leukocyte rolling, adhesion, and migration 
through the endothelium of vein wall and valve [21]. 
Plasma levels of VCAM-1, angiotensin-converting en-
zyme, endothelial leukocyte adhesion molecule, and 
L-Selectin are also increased in varicose veins [24, 25].
The endothelial glycocalyx (GCX) — structure 
responsible for the prevention of leukocyte adhesion, 
thrombosis, and inflammation in CVD is injured by the 
altered shear stress and mechanical forces on the wall 
of the vein, which leads to loss of GCX [26]. In the vein 
wall of varicose veins, there is an increased level of 
degraded, sulfated glycosaminoglycans, which confirms 
the GCX disruption [27].
Matrix metalloproteinases — proteolytic enzymes 
identified in many tissues and organs including the 
venous system, play a crucial role in tissue remodeling 
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and turnover of the collagen, elastin, and other pro- 
teins [28]. Overexpression of MMPs and cytokines has 
an important effect on the venous wall and valves caus-
ing tissue destruction with skin changes and formation 
of the ulcer [29, 30]. In vein samples from the patients 
with CVD, have been found a variety of MMPs such as: 
MMP-1, -2, -3, -8, -9, -12, and -13 [31]. Their role in-
cludes degradation of adventitial extracellular matrix, as 
well as collagen bundles and elastin in the medial layer, 
having also potential early effect on venous dilation [32]
Cytokines were proven to play an important role at 
different stages of CVD. The majority of pro-inflamma-
tory cytokines (IL-1b, IL-4, IL-6, IL-8, IL-12p40, IL-13, 
g-csf, gM-csf, McP-1, ifn-g, tnf-a, MiP-1a, and 
MiP-1b) were found to be elevated in ulcer tissue from 
patients with CVD [33].
Levels of inflammatory biomarkers in  
patients undergoing compression therapy
Several studies were performed to investigate the 
influence of compression therapy on the levels of var-
ious inflammatory biomarkers in patients with CVD. 
The interesting study held by Beidler et al. investigat-
ed changes in inflammatory cytokine levels in ulcer tissue 
from patients with CVD treated with a high-grade 3- or 
4-layer compression bandage system for 4 weeks. The 
study group consisted of 30 limbs with untreated CVD 
and leg ulceration. Tissue samples were obtained using 
biopsy from healthy and ulcerated tissue before and after 
therapy. Cytokine levels were measured using a multi-
plexed protein assay. The majority of pro-inflammatory 
cytokine levels (IL-1b, IL-6, IL-8, IL-12p40, IL-13, G-CSF, 
gM-csf, McP-1, ifn-g, tnf-a, MiP-1a, MiP-1b) were 
elevated in ulcer tissue, in comparison with controls. 
Most of the investigated molecule levels (IL-1b, IL-6, IL-8, 
IL-12p40, G-CSF, GM-CSF, IFN-g, tnf-a) significantly 
decreased after the compression therapy. On the other 
hand, the level of an anti-inflammatory cytokine, IL-1Ra, 
increased after 4 weeks of treatment. Ulcers with a high-
er level of il-1a, il-1b, ifn-g, IL-12p40, and GM-CSF 
were more likely to heal rapidly [33]. 
 In an earlier study, Murphy et al. investigated se-
rum levels of VEGF and TNF-a in a group of 8 patients 
undergoing 4 weeks of treatment with 4-layered, grad-
uated compression therapy. Serum samples were taken 
from the superficial veins of the lower limb before and 
after the treatment. Serum from the arms of the same 
patients was used as a control. The level of VEGF and 
tnf-a were measured with ELISA assay. All patients 
had elevated cytokine levels before the treatment com-
pared with the control. In each case, the reduction to 
below control values in the levels of VEGF and TNF-a 
was observed [34]. 
 Another study, held by Gohel et al. [35], com-
prised 80 patients with chronic leg ulceration treated 
with multilayer compression bandaging. Inflammatory 
biomarkers were measured in the wound fluid and in 
the venous blood taken from the antecubital vein at 
recruitment and after 5 weeks as well as the size of 
ulceration. Levels of proinflammatory molecules were 
measured using the ELISA technique. Median ulcer size 
reduced from 4.4 cm2 to 2.2 cm2 after the treatment. 
The volume of wound fluid strongly correlated with the 
size of an ulcer. Among all of the investigated cytokines 
and factors (TNFa, il1b, bfgf, Vegf, tgfb 1, MMP2, 
MMP9) only bFGF showed a significant positive corre-
lation between its concentration in wound fluid and an 
ulcer size. Changes in wound fluid TGFb 1 concentra-
tions inversely correlated with changes in ulcer size. 
Other factors did not show significant correlations with 
ulcer healing. Also, the correlation between the wound 
fluid and serum cytokine concentrations was poor [35]. 
 In a 2008 study, Beidler et al. [36] investigated lev-
els of matrix metalloproteinases (MMPs) in a leg ulcer 
tissue of patients with CVD before and after 4 weeks 
of high-strength compression therapy. The study group 
included 29 patients with untreated CVD and leg ulcer-
ation. Tissue samples were obtained by biopsies from 
healthy tissues and from ulcerated tissue before and 
after therapy. MMPs were measured using a multiplexed 
protein assay. MMP1, 2, 3, 8, 9, 12, and 13 levels were 
elevated in ulcer tissue comparing with healthy tissue. 
Levels of MMP3, 8, and 9 significantly decreased after 
the compression therapy. A decrease in MMP1, 2 and 3 
levels was linked with significantly higher rates of ulcer 
healing at the end of treatment [36]. 
 A more recent study, performed by Caimi et al. 
investigated plasma concentration levels of gelatinases 
(MMP-2 and MMP-9) and their inhibitors (TIMP-1 and 
TIMP-2) in a group of 36 patients with CVD and ve-
nous leg ulcers, before and after the treatment with 
a multi-layer bandaging system. The levels of gelatinases 
and their inhibitors were measured in fasting venous 
blood using an ELISA kit. A significantly higher level of 
gelatinases and their inhibitors was observed in patients 
with leg ulcers, comparing with normal controls. Heal-
ing of the ulcers after the therapy was associated with 
a decrease in MMP-9 and TIMP-1 levels and in MMP-2/ 
/TIMP-2 ratio compared to the baseline values. How-
ever, even after the therapy, the levels of all examined 
parameters were higher than in the control group [37].
Conclusions
In the last years, inflammation has been proven to 
play an important role in the pathophysiology of chronic 
venous disease.
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Compression therapy remains the gold standard of 
the conservative treatment of CVD in all stages, and has 
been proven to improve the healing of venous ulcers.
Many studies reported an increased expression of 
inflammatory markers in vitro, in pre-clinical studies, 
and in patients with CVD.
Several inflammatory molecules, chemokines, vaso-
active agents, selectins, and prothrombotic precursors, 
such as ICAM-1, MCP-1, macrophage inflammatory 
protein 1b, VCAM, L-selectin, E-selectin, IL-1b, il-4, 
IL-6, IL-8, IL-12p40, IL-13, G-CSF, GM-CSF, IFN-g, 
tnf-a, MiP-1a, as well as matrix metalloproteinases 
MMP-1, -2, -3, -8, -9, -12, and -13 were identified in 
patients with CVD. 
Several studies were performed to investigate the 
influence of compression therapy on the level of various 
inflammatory biomarkers in patients with CVD. 
Presented studies showed a reduction in levels of 
inflammatory biomarkers such as IL 1b, IL-6, IL-8, IL-
12p40, G-CSF, GM-CSF, IFN-g, tnf-a, Vegf, MMP 3, 
8, 9 and TIMP-1 after the therapy. 
Not all biomolecular mechanisms of the healing ef-
fect of compression therapy on venous leg ulcers have 
been well understood, so further studies regarding this 
topic may be needed.
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